Comparing two venetoclax-based chemotherapy strengths for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years or older.
- You must have a new diagnosis of acute myeloid leukemia (AML) that has not yet been treated with strong chemotherapy (though hydroxyurea to lower blood counts is okay).
- You must be generally healthy enough to undergo intensive chemotherapy, meaning you can manage daily activities with little or no help and have adequate liver, kidney, and heart function.
- You must not have certain genetic subtypes of AML (such as acute promyelocytic leukemia or those with specific fusion genes like RUNX1-RUNX1T1 or CBFB-MYH11) or a FLT3 mutation.
- You must not have active heart disease or a serious infection (like active tuberculosis).
- You must not have another cancer that needs treatment at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.